BI signs deal with MiNA to develop liver disease drugs
Boehringer Ingelheim | November 09, 2017
The German drugmaker is linking with UK-based MiNA Therapeutics to develop novel compounds to treat fibrotic liver diseases such as NASH, based on MiNA’s small activating RNA (siRNA) therapeutics platform.